Data Sheet

Product Name:	SPHINX
Cat. No.:	CS-0148722
CAS No.:	848057-98-7
Molecular Formula:	$C_{17}H_{17}F_3N_2O_3$
Molecular Weight:	354.32
Target:	SRPK
Pathway:	Cell Cycle/DNA Damage
Solubility:	DMSO : 50 mg/mL (141.12 mM; ultrasonic and warming and heat to 60°C)



BIOLOGICAL ACTIVITY:

SPHINX is a selective **SRPK1** inhibitor with an **IC_{50}** value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD[1]. IC50 & Target:IC50: 0.58 μM (SRPK1)[1] **In Vitro:**SPHINX (10 μM; 2 h) affects EGF-induced phosphorylation of SRSF1 and SRSF2[1].
SPHINX (5 μM; 24 h) reduces the expression of VEGF165 relative to GAPDH control either in primary RPE and ARPE-19 cell lines[1].
In Vivo:SPHINX (10 ng; i.o. on laser photocoagulation day 0 and day 7) affects neovascular growth in vivo[1].
SPHINX (25 ng; i.o. on laser photocoagulation day 0 and day 7) affects the CNV area in CNV rats[1].

References:

[1]. Gammons MV, et al. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Invest Ophthalmol Vis Sci. 2013 Sep 5;54(9):6052-62.

CAIndexNames:

2-Furancarboxamide, 5-methyl-N-[2-(4-morpholinyl)-5-(trifluoromethyl)phenyl]-

SMILES:

O=C(C1=CC=C(C)O1)NC2=CC(C(F)(F)F)=CC=C2N3CCOCC3

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA